Long-acting lenacapavir is a breakthrough for preventing HIV infection, but HIV vaccine research must continue

References

[1] UNAIDS. The urgency of now: AIDS at a crossroads. Geneva: Joint United Nations Programme on HIV/AIDS. 2024. Available at the website of UNAIDS

[2] Sun C , Zuo T , Wen Z . First clinical study of germline-targeting strategy: one step closer to a successful bnAb-based HIV vaccine. Innovation (Camb) 2023; 4(1): 100374

[3] Segal-Maurer S , DeJesus E , Stellbrink HJ , Castagna A , Richmond GJ , Sinclair GI , Siripassorn K , Ruane PJ , Berhe M , Wang H , Margot NA , Dvory-Sobol H , Hyland RH , Brainard DM , Rhee MS , Baeten JM , Molina JM; CAPELLA Study Investigators . Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med 2022; 386(19): 1793–1803

[4] Rai MA , Blazkova J , Kardava L , Justement JS , Shi V , Manning MR , Shahid A , Dong W , Kennedy BD , Sewack AB , Higgins J , Buckner CM , Gittens K , West RE 3rd , Devanathan AS , Mangusan R , Lurain K , Ramaswami R , Yarchoan R , Sneller MC , Pau AK , Brumme ZL , Moir S , Chun TW . Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir. Nat Med 2025; 31(2): 427–432

[5] Grant RM , Lama JR , Anderson PL , McMahan V , Liu AY , Vargas L , Goicochea P , Casapía M , Guanira-Carranza JV , Ramirez-Cardich ME , Montoya-Herrera O , Fernández T , Veloso VG , Buchbinder SP , Chariyalertsak S , Schechter M , Bekker LG , Mayer KH , Kallás EG , Amico KR , Mulligan K , Bushman LR , Hance RJ , Ganoza C , Defechereux P , Postle B , Wang F , McConnell JJ , Zheng JH , Lee J , Rooney JF , Jaffe HS , Martinez AI , Burns DN , Glidden DV; iPrEx Study Team . Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587–2599

[6] Wen Z , Shi M , Sun C . Treatment as the best prevention: twice-yearly lenacapavir, a game changer in ending the AIDS epidemic. Viruses 2024; 16(9): 1368

[7] Landovitz RJ , Donnell D , Clement ME , Hanscom B , Cottle L , Coelho L , Cabello R , Chariyalertsak S , Dunne EF , Frank I , Gallardo-Cartagena JA , Gaur AH , Gonzales P , Tran HV , Hinojosa JC , Kallas EG , Kelley CF , Losso MH , Madruga JV , Middelkoop K , Phanuphak N , Santos B , Sued O , Valencia Huamaní J , Overton ET , Swaminathan S , Del Rio C , Gulick RM , Richardson P , Sullivan P , Piwowar-Manning E , Marzinke M , Hendrix C , Li M , Wang Z , Marrazzo J , Daar E , Asmelash A , Brown TT , Anderson P , Eshleman SH , Bryan M , Blanchette C , Lucas J , Psaros C , Safren S , Sugarman J , Scott H , Eron JJ , Fields SD , Sista ND , Gomez-Feliciano K , Jennings A , Kofron RM , Holtz TH , Shin K , Rooney JF , Smith KY , Spreen W , Margolis D , Rinehart A , Adeyeye A , Cohen MS , McCauley M , Grinsztejn B; HPTN 083 Study Team . Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021; 385(7): 595–608

[8] Bekker LG , Das M , Abdool Karim Q , Ahmed K , Batting J , Brumskine W , Gill K , Harkoo I , Jaggernath M , Kigozi G , Kiwanuka N , Kotze P , Lebina L , Louw CE , Malahleha M , Manentsa M , Mansoor LE , Moodley D , Naicker V , Naidoo L , Naidoo M , Nair G , Ndlovu N , Palanee-Phillips T , Panchia R , Pillay S , Potloane D , Selepe P , Singh N , Singh Y , Spooner E , Ward AM , Zwane Z , Ebrahimi R , Zhao Y , Kintu A , Deaton C , Carter CC , Baeten JM , Matovu Kiweewa F; PURPOSE 1 Study Team . Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med 2024; 391(13): 1179–1192

[9] KelleyCFAcevedo-QuiñonesMAgwuALAvihingsanonABensonPBlumenthalJBrinsonCBritesCCahnPCantosVDClarkJClementMCreticosCCrofootGDiazRSDoblecki-LewisSGallardo-CartagenaJAGaurAGrinsztejnBHasslerSHinojosaJCHodgeTKaplanRLacerdaMLaMarcaALossoMHValdezMadruga JMayerKHMillsAMounzerKNdlovuNNovakRMPerezRios APhanuphakNRamgopalMRuanePJSánchezJSantosBSchinePSchreibmanTSpencerLYVanGerwen OTVasconcelosRVasquezJGZwaneZCoxSDeatonCEbrahimiRWongPSinghRBrownLBCarterCCDasMBaetenJMOgbuaguO; PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med 2024; [Epub ahead of print] doi: 10.1056/NEJMoa2411858

[10] The Lancet HIV . Lenacapavir licenses will not deliver on all opportunities. Lancet HIV 2024; 11(11): e717

Acknowledgements

This study was supported by the National Natural Science Foundation of China (Nos. 82472267 and 82271786), and the Key Subject of Nanshan District of Shenzhen for AIDS Surveillance and Prevention.

Compliance with ethics guidelines

Conflicts of interest Caijun Sun, Linghua Li, Pingchao Li, Weiping Cai, Xiaoping Tang, Yiming Shao, and Ling Chen have declared that no conflict of interest exists.

This manuscript is a comment article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

RIGHTS & PERMISSIONS

2025 Higher Education Press